US OptionsDetailed Quotes
KRYS241220C220000
- 2.10
- 0.000.00%
15min DelayClose Nov 26 16:00 ET
0.00High0.00Low
2.10Open2.10Pre Close0 Volume42 Open Interest220.00Strike Price0.00Turnover44.90%IV13.02%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry2.10Extrinsic Value100Contract SizeAmericanOptions Type0.1817Delta0.0118Gamma93.58Leverage Ratio-0.1296Theta0.0216Rho17.00Eff Leverage0.1316Vega
Krystal Biotech Stock Discussion
Sign in to post a comment
Banks: $JPMorgan (JPM.US)$ $Wells Fargo & Co (WFC.US)$ $Bank of America (BAC.US)$
Capital Markets: $UP Fintech (TIGR.US)$ $Cipher Mining (CIFR.US)$ $CleanSpark (CLSK.US)$
Biotechnology: $Genfit (GNFT.US)$ $Spyre Therapeutics (SYRE.US)$ $Krystal Biotech (KRYS.US)$
Software: $Verb Technology (VERB.US)$ $SurgePays (SURG.US)$ $Uber Technologies (UBER.US)$
Asset Management: $Westwood Holdings (WHG.US)$ $BrightSphere Investment (BSIG.US)$ $Blackrock (BLK.US)$
Specialty Industrial Machinery: $JE Cleantech Holdings Limited (JCSE.US)$ $Taylor Devices (TAYD.US)$ $CSW Industrials (CSWI.US)$
...
Capital Markets: $UP Fintech (TIGR.US)$ $Cipher Mining (CIFR.US)$ $CleanSpark (CLSK.US)$
Biotechnology: $Genfit (GNFT.US)$ $Spyre Therapeutics (SYRE.US)$ $Krystal Biotech (KRYS.US)$
Software: $Verb Technology (VERB.US)$ $SurgePays (SURG.US)$ $Uber Technologies (UBER.US)$
Asset Management: $Westwood Holdings (WHG.US)$ $BrightSphere Investment (BSIG.US)$ $Blackrock (BLK.US)$
Specialty Industrial Machinery: $JE Cleantech Holdings Limited (JCSE.US)$ $Taylor Devices (TAYD.US)$ $CSW Industrials (CSWI.US)$
...
4
1
The strong revenue growth is mirrored in the share price gain. Despite the strong run, top performers like Krystal Biotech can continue winning for decades. The stock's recent performance improvement may suggest real business momentum.
1
High insider ownership at Krystal Biotech implies management's alignment with shareholders. Yet, no insider transactions in the last three months and significant share selling over the past year are concerning.
Analysts' optimism soars as they forecast Krystal Biotech to break even soon, given its massive projected annual growth rate of 68%. The firm's debt-free operation, unusual in loss-making biotech companies, lowers investment risk.
Market rewards Krystal Biotech's significant revenue growth despite recent stock price decline. Bullish sentiment suggests ongoing positive trend, irrespective of the current drop.
Despite the substantial selling of shares over the past year, insiders' ownership is still considerable. However, the lack of recent insider purchases could be of concern. Investors are advised to also consider the potential risks facing Krystal Biotech.
1
Gainers:
• $La-Z-Boy (LZB.US)$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals (ENTA.US)$ +6.7% (ENTA files patent infringement lawsuit against $Pfizer (PFE.US)$)
• $Ikena Oncology (IKNA.US)$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma (BBIO.US)$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech (KRYS.US)$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
• $La-Z-Boy (LZB.US)$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals (ENTA.US)$ +6.7% (ENTA files patent infringement lawsuit against $Pfizer (PFE.US)$)
• $Ikena Oncology (IKNA.US)$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma (BBIO.US)$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech (KRYS.US)$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
8
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
No comment yet
El Gato99 : $240 by early November, Jamie delivers again.